- Home
- STRW vs TARA Comparison
STRW vs TARA Comparison
Compare STRW & TARA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STRW
- TARA
- Stock Information
- Founded
- STRW 2015
- TARA N/A
- Country
- STRW United States
- TARA United States
- Employees
- STRW N/A
- TARA N/A
- Industry
- STRW Real Estate Investment Trusts
- TARA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- STRW Real Estate
- TARA Health Care
- Exchange
- STRW Nasdaq
- TARA Nasdaq
- Market Cap
- STRW 133.6M
- TARA 126.5M
- IPO Year
- STRW N/A
- TARA N/A
- Fundamental
- Price
- STRW $10.99
- TARA $3.05
- Analyst Decision
- STRW Strong Buy
- TARA Strong Buy
- Analyst Count
- STRW 4
- TARA 7
- Target Price
- STRW $13.83
- TARA $20.67
- AVG Volume (30 Days)
- STRW 46.0K
- TARA 255.2K
- Earning Date
- STRW 08-11-2025
- TARA 08-05-2025
- Dividend Yield
- STRW 5.08%
- TARA N/A
- EPS Growth
- STRW 34.22
- TARA N/A
- EPS
- STRW 0.58
- TARA N/A
- Revenue
- STRW $126,557,000.00
- TARA N/A
- Revenue This Year
- STRW $15.21
- TARA N/A
- Revenue Next Year
- STRW $2.21
- TARA N/A
- P/E Ratio
- STRW $19.13
- TARA N/A
- Revenue Growth
- STRW 22.41
- TARA N/A
- 52 Week Low
- STRW $8.70
- TARA $1.60
- 52 Week High
- STRW $12.90
- TARA $10.48
- Technical
- Relative Strength Index (RSI)
- STRW 58.72
- TARA 41.66
- Support Level
- STRW $10.43
- TARA $3.12
- Resistance Level
- STRW $11.25
- TARA $3.24
- Average True Range (ATR)
- STRW 0.51
- TARA 0.18
- MACD
- STRW 0.10
- TARA -0.00
- Stochastic Oscillator
- STRW 79.32
- TARA 14.81
About STRW Strawberry Fields REIT Inc.
Strawberry Fields REIT Inc is a self-managed and self-administered company that specializes in the acquisition, ownership and triple-net leasing of skilled nursing facilities and other post-acute healthcare properties.
About TARA Protara Therapeutics Inc.
Protara Therapeutics Inc is committed to identifying and advancing transformative therapies for people with cancer and rare diseases. The company discovers, develops and delivers breakthrough therapies to people who have limited treatment options. Its portfolio includes its program, TARA-002, being developed for the treatment of lymphatic malformations, and intravenous (IV) choline chloride, a phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease (IFALD).